Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study.
Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study.
复制标题
DOI：
10.3390/cancers14163928
复制
发表时间：
2022-08-15
期刊：
影响因子：
5.2
通讯作者：
Thureau, Sebastien
中科院分区：
文献类型：
--
作者：
Roge, Maximilien;Salleron, Julia;Kirova, Youlia;Guigo, Marin;Cailleteau, Axel;Levy, Christelle;Leheurteur, Marianne;Nebbache, Rafik;Del Campo, Eleonor Rivin;Lazarescu, Ioana;Servagi, Stephanie;Aumont, Maud;Thariat, Juliette;Thureau, Sebastien
关键词：
炎性乳腺癌是一种罕见的预后不良的疾病，尤其是三阴性亚型。本研究探讨新辅助化疗后肿瘤和淋巴结反应的独立预后价值。研究表明，对于HR和HER2状态，肿瘤和淋巴结反应没有相同的预后价值。我们确定了一组伴有淋巴结残留疾病的三阴性炎性乳腺癌患者，他们的辅助治疗强化可能值得研究。炎症性乳腺癌（IBC）是一种罕见的预后不良的疾病。我们分析了非转移性IBC患者的生存结局和肿瘤或淋巴结反应的预后价值，以评估其在IBC亚型中的个体预后影响。这项回顾性多中心研究纳入了2010年至2017年间诊断为IBC的患者，以说明法国7个肿瘤中心新辅助全身治疗和现代放疗的进展。纳入并分析了317例患者。中位随访52个月后，三阴性（TN）患者的5年DFS较低（50.1%比63.6%;p < 0.0001）。经多因素分析，三阴性组中淋巴结不完全缓解是唯一显著的预后因素（HR:6.06）。在新辅助化疗后出现淋巴结反应的情况下，TN-IBC的不良预后得到逆转。与淋巴结反应相比，乳房反应似乎不是TN-IBC患者预后的决定性因素。尽管新辅助治疗有所改善，但IBC仍与不良预后相关。在TN-IBC患者中，与其他任何组相比，缺乏病理完全淋巴结反应与较差的生存率相关。治疗强化策略值得探讨。
Inflammatory breast cancer is a rare entity associated with a poor prognosis, especially for the triple-negative subtype. This study investigates the independent prognostic value of tumour and nodal responses after neoadjuvant chemotherapy. It shows that tumour and lymph node responses did not have the same prognostic value regarding HR and HER2 statuses. We identified a subgroup of patients with triple-negative inflammatory breast cancer with residual lymph node disease for whom adjuvant treatment intensification may be worth investigating. Inflammatory breast cancer (IBC) is a rare entity with a poor prognosis. We analysed the survival outcomes of patients with nonmetastatic IBC and the prognostic value of tumour or nodal responses to assess their individual prognostic impact across IBC subtypes. This retrospective multicentre study included patients diagnosed with IBC between 2010 and 2017 to account for advances in neoadjuvant systemic therapies and modern radiotherapy at seven oncology centres in France. Three hundred and seventeen patients were included and analysed. After a median follow-up of 52 months, the 5-year DFS was lower for triple-negative (TN) (50.1% vs. 63.6%; p < 0.0001). After multivariate analyses, incomplete nodal response was the only significant prognostic factor in the triple-negative group (HR:6.06). The poor prognosis of TN-IBC was reversed in the case of nodal response after neoadjuvant chemotherapy. Breast response does not appear to be a decisive prognostic factor in patients with TN-IBC compared to lymph node response. Despite improvements in neoadjuvant treatments, IBC remains associated with a poor prognosis. In TN-IBC patients, lack of pathological complete node response was associated with poorer survival than any other group. Treatment intensification strategies are worth investigating.
登录
查看更多内容
影响因子：
45.3
作者：
Rueth, Natasha M.;Lin, Heather Y.;Babiera, Gildy
通讯作者：
Babiera, Gildy
影响因子：
3.1
作者：
Cristofanilli, Massimo;Gonzalez-Angulo, Ana Maria;Hortobagyi, Gabriel N
通讯作者：
Hortobagyi, Gabriel N
影响因子：
3.7
作者：
Warren, Laura E. G.;Guo, Hao;Bellon, Jennifer R.
通讯作者：
Bellon, Jennifer R.
影响因子：
10.3
作者：
Hance, KW;Anderson, WF;Levine, PH
通讯作者：
Levine, PH
影响因子：
3.8
作者：
van Uden, Dominique J. P.;van Maaren, Marissa C.;de Wilt, Johannes H. W.
通讯作者：
de Wilt, Johannes H. W.